Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.31 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19959068 | 0.87 | ALDH1A1 (0.34) | KDM4ENPC1ALDH1A1CHRM5ADRA2C | |
| SCHEMBL22296947 | 0.84 | HSD11B1 (0.37) | HSD11B1GBA1NPC1CHRM5ADRA2C | |
| SCHEMBL26419154 | 0.83 | CHRM5 (0.41) | CHRM5ADRA2C | |
| SCHEMBL21664721 | 0.81 | HSD11B1 (0.35) | HSD11B1GBA1NPC1CHRM5ADRA2C | |
| SCHEMBL19959071 | 0.81 | KCNH2 (0.36) | ALDH1A1 | |
| SCHEMBL25728588 | 0.80 | ACHE (0.35) | HSD11B1NPC1ALDH1A1CHRM5ADRA2C | |
| SCHEMBL26419153 | 0.80 | CHRM5 (0.46) | CHRM5ADRA2C | |
| SCHEMBL20234755 | 0.78 | ALDH1A1 (0.32) | HSD11B1GBA1ALDH1A1 | |
| SCHEMBL21341636 | 0.78 | ALDH1A1 (0.32) | HSD11B1GBA1ALDH1A1 | |
| SCHEMBL26029865 | 0.78 | ALDH1A1 (0.32) | HSD11B1GBA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230338371-A1 | PHARMACEUTICAL COMPOSITIONS OF PROTAC COMPOUNDS AND USES THEREOF | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-11220515-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2022-01-11 | — | — | US | disclosed |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | UNIV YALE (US) | 2020-04-23 | — | — | US | disclosed |
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190233433-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2019-08-01 | — | — | US | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220515-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | HSD11B1 4159/4885GBA1 3275/4885KDM4E 498/4885 |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | HSD11B1 4059/4885GBA1 3178/4885KDM4E 1071/4885 |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | HSD11B1 4225/4885GBA1 3209/4885KDM4E 1613/4885 |
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | HSD11B1 4164/4885GBA1 796/4885KDM4E 1466/4885 |
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | HSD11B1 2752/4885GBA1 2964/4885KDM4E 1787/4885 |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | HSD11B1 2365/4885GBA1 4507/4885KDM4E 1438/4885 |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | HSD11B1 4420/4885GBA1 1682/4885KDM4E 2053/4885 |
| US-20190233433-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | HSD11B1 4159/4885GBA1 3275/4885KDM4E 498/4885 |
| US-20230338371-A1 | PHARMACEUTICAL COMPOSITIONS OF PROTAC COMPOUNDS AND USES THEREOF | ADRM1, PSMC1, UBE3C | HSD11B1 2982/4885GBA1 2384/4885KDM4E 1923/4885 |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | HSD11B1 4209/4885GBA1 1431/4885KDM4E 1254/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | HSD11B1 3595/4885GBA1 2126/4885KDM4E 1205/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | HSD11B1 4420/4885GBA1 1682/4885KDM4E 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.